MA54879A - Inhibiteurs d'enpp1 et méthodes de modulation de réponse immunitaire - Google Patents

Inhibiteurs d'enpp1 et méthodes de modulation de réponse immunitaire

Info

Publication number
MA54879A
MA54879A MA054879A MA54879A MA54879A MA 54879 A MA54879 A MA 54879A MA 054879 A MA054879 A MA 054879A MA 54879 A MA54879 A MA 54879A MA 54879 A MA54879 A MA 54879A
Authority
MA
Morocco
Prior art keywords
immune response
modulation methods
response modulation
enpp1 inhibitors
enpp1
Prior art date
Application number
MA054879A
Other languages
English (en)
Inventor
Volker Boehnert
Jacqueline Ann Carozza
Lingyin Li
Mark Smith
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of MA54879A publication Critical patent/MA54879A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D201/00—Preparation, separation, purification or stabilisation of unsubstituted lactams
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/60—Quinoline or hydrogenated quinoline ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • C07F9/65128—Six-membered rings having the nitrogen atoms in positions 1 and 3 condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA054879A 2019-02-01 2020-01-30 Inhibiteurs d'enpp1 et méthodes de modulation de réponse immunitaire MA54879A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962800283P 2019-02-01 2019-02-01
US201962814745P 2019-03-06 2019-03-06

Publications (1)

Publication Number Publication Date
MA54879A true MA54879A (fr) 2021-12-08

Family

ID=71842335

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054879A MA54879A (fr) 2019-02-01 2020-01-30 Inhibiteurs d'enpp1 et méthodes de modulation de réponse immunitaire

Country Status (18)

Country Link
US (2) US20220289775A1 (fr)
EP (1) EP3917536A4 (fr)
JP (2) JP7777332B2 (fr)
KR (1) KR20210124265A (fr)
CN (1) CN113677350B (fr)
AU (2) AU2020214628C1 (fr)
BR (1) BR112021015098A2 (fr)
CA (1) CA3128044A1 (fr)
CL (1) CL2021002002A1 (fr)
CO (1) CO2021010186A2 (fr)
IL (2) IL284961B2 (fr)
MA (1) MA54879A (fr)
MX (1) MX2021009269A (fr)
PE (1) PE20212306A1 (fr)
PH (1) PH12021551833A1 (fr)
SG (1) SG11202108288YA (fr)
TW (2) TWI849048B (fr)
WO (1) WO2020160333A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240151869A (ko) 2017-09-08 2024-10-18 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 Enpp1 저해제 및 암의 치료용의 이의 용도
WO2020140001A1 (fr) * 2018-12-28 2020-07-02 Riboscience Llc Dérivés de quinazoline utilisés en tant qu'inhibiteurs d'ectonucléotide pyrophosphatase/phosphodiestérase 1
ES2960987T3 (es) 2019-04-12 2024-03-07 Riboscience Llc Derivados de heteroarilo bicíclicos como inhibidores de la ectonucleótido pirofosfatasa fosfodiesterasa 1
KR20220068243A (ko) * 2019-09-23 2022-05-25 난징 젱시앙 파마슈티칼스 컴퍼니 리미티드 포스포디에스테라제 억제제 및 용도
EP4146269A4 (fr) * 2020-05-04 2024-08-21 Angarus Therapeutics, Inc. Inhibiteurs d'enpp1 et méthodes de modulation de réponse immunitaire
JP2023529557A (ja) * 2020-05-04 2023-07-11 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 抗ｅｎｐｐ１抗体の阻害
TW202208337A (zh) 2020-05-04 2022-03-01 美商佛拉斯托醫療公司 Ｅｎｐｐ１之亞胺基硫烷酮抑制劑
TW202214640A (zh) 2020-06-16 2022-04-16 美商佛拉斯托醫療公司 Ｅｎｐｐ１之雜環抑制劑
US20230365540A1 (en) * 2020-09-09 2023-11-16 The Regents Of The University Of California Small molecule inhibitors of enpp1
JP2023549738A (ja) * 2020-10-30 2023-11-29 １シーバイオ， インコーポレイテッド エクトヌクレオチドピロホスファターゼ－ホスホジエステラーゼ－１（ｅｎｐｐ１）阻害物質及びそれらの使用
WO2022125614A1 (fr) * 2020-12-09 2022-06-16 Stingray Therapeutics, Inc. Phosphonates comme inhibiteurs d'enpp1 et de cdnp
CN116600813A (zh) * 2020-12-09 2023-08-15 斯汀格瑞治疗股份有限公司 作为enpp1和cdnp抑制剂的膦酸盐
WO2022125613A1 (fr) * 2020-12-09 2022-06-16 Stingray Therapeutics, Inc. Phosphonates en tant qu'inhibiteurs d'enpp1 et cdnp
WO2022197734A1 (fr) * 2021-03-16 2022-09-22 Riboscience Llc Dérivés de boronate hétéroaryle bicycliques utilisés comme inhibiteurs de l'ecto-nucléotide pyrophosphatase/phosphodiestérase 1
WO2022199635A1 (fr) * 2021-03-25 2022-09-29 南京明德新药研发有限公司 Dérivés de benzylaminoquinazoline
CN115536696B (zh) * 2021-06-29 2023-07-14 上海齐鲁制药研究中心有限公司 Enpp1抑制剂
CN115702939A (zh) * 2021-08-05 2023-02-17 杭州星鳌生物科技有限公司 载物脂质体的多靶点复合体及含其的载药平台与应用
EP4395786A4 (fr) * 2021-09-03 2025-07-23 Angarus Therapeutics Inc Inhibiteurs d'enpp1 et cellules immunitaires exprimant des récepteurs d'antigènes chimériques
JP2024533433A (ja) * 2021-09-10 2024-09-12 ハイヘ バイオファーマ カンパニー，リミティド Ｅｎｐｐ１阻害活性を有するヒドロキサム酸系化合物及びその使用
KR20230040756A (ko) 2021-09-16 2023-03-23 삼성전자주식회사 위상 고정 루프의 모니터링 회로 및 이의 동작 방법
WO2023073560A1 (fr) 2021-10-26 2023-05-04 Grant Demartino Industries Llc Nanoensemble piézoélectrique magnétostrictif en tant qu'agent chimiothérapeutique contre le cancer
WO2023077083A1 (fr) * 2021-10-29 2023-05-04 Angarus Therapeutics, Inc. Inhibiteurs d'enpp1 en tant qu'inhibiteurs de métastases
TWI896926B (zh) * 2022-01-21 2025-09-11 大陸商上海海和藥物研究開發股份有限公司 膦酸類化合物及其前藥、它們的製備方法及用途
CN118488950A (zh) * 2022-04-11 2024-08-13 上海齐鲁制药研究中心有限公司 Enpp1抑制剂
CN119677742A (zh) * 2022-08-01 2025-03-21 斯拉瓦蒂人工智能科技私人有限公司 一种新型外核苷酸焦磷酸酶/磷酸二酯酶1（enpp1）抑制剂及其用途
WO2024127343A1 (fr) * 2022-12-16 2024-06-20 Sravathi Ai Technology Private Limited Inhibiteurs de l'ectonucléotide pyrophosphatase/phosphodiestérase 1 (enpp-1)
JP2026509361A (ja) * 2023-03-08 2026-03-18 ペトラジェン・インコーポレイテッド 改良されたｅｎｐｐ１阻害剤およびその使用
EP4694894A1 (fr) * 2023-04-12 2026-02-18 Agenus Inc. Méthodes de traitement du cancer faisant appel à un anticorps anti-ctla4 et à un inhibiteur d'enpp1
CN118105494A (zh) * 2024-01-24 2024-05-31 苏州大学 一种靶向enpp1在系统性红斑狼疮治疗中的应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA228044A (fr) 1923-01-16 Thomas Noble Boughton Matrice a faconner des boulons
CA190896A (fr) 1919-02-24 1919-06-17 Josephat C. Bergeron Dispositif de montre
GB1460389A (en) * 1974-07-25 1977-01-06 Pfizer Ltd 4-substituted quinazoline cardiac stimulants
DE3319795A1 (de) * 1983-06-01 1984-12-06 Hoechst Ag, 6230 Frankfurt Verfahren zur herstellung von phosphonsaeureestern
US7132427B2 (en) 2001-06-21 2006-11-07 Ariad Pharmaceuticals, Inc. Quinazolines and uses thereof
JP2009242240A (ja) 2006-08-04 2009-10-22 Mebiopharm Co Ltd 含ホウ素キナゾリン誘導体
JO3598B1 (ar) 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
WO2008113161A1 (fr) 2007-03-19 2008-09-25 Ulysses Pharmaceutical Products Inc. Promédicaments phosphates de quinazolinyle nitrofurannes, procédés d'obtention et utilisation de ces promédicaments
US10543207B2 (en) * 2008-12-31 2020-01-28 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
CN102971313A (zh) 2010-04-14 2013-03-13 百时美施贵宝公司 新颖的葡糖激酶激活剂及其使用方法
US8883791B2 (en) * 2010-09-29 2014-11-11 Intervet Inc. N-heteroaryl compounds with cyclic bridging unit for the treatment of parasitic diseases
CA2860234A1 (fr) 2011-12-22 2013-06-27 Alios Biopharma, Inc. Analogues de nucleotide phosphorothioate substitue
ES2849998T3 (es) 2014-09-22 2021-08-24 National Health Res Inst Compuestos heterocíclicos y su uso
WO2016049568A1 (fr) * 2014-09-25 2016-03-31 Araxes Pharma Llc Méthodes et compositions permettant l'inhibition de la ras
WO2016161952A1 (fr) 2015-04-07 2016-10-13 广东众生药业股份有限公司 Inhibiteur de la tyrosine kinase et composition pharmaceutique le comprenant
WO2017147328A1 (fr) 2016-02-23 2017-08-31 Portola Pharmaceuticals, Inc. Composés se liant à la proprotéine convertase subtilisine/kexine de type 9 (pcsk9)
US10518257B2 (en) * 2017-05-04 2019-12-31 Exxonmobil Research And Engineering Company Metal organic frameworks, their synthesis and use
WO2018229139A1 (fr) 2017-06-14 2018-12-20 Fundación Para La Investigación Médica Aplicada Nouveaux composés destinés à être utilisés pour le cancer
WO2019023635A1 (fr) 2017-07-27 2019-01-31 Stingray Therapeutics, Inc. Série de 3 h-imidazo(4,5-c)pyridine substituée et de 1h-pyrrolo(2,3-c)pyridine d'une nouvelle ectonucléotide pyrophosphatase/phosphodiestérase-1 (enpp1) et stimulateur pour un modulateur de gènes d'interféron (sting) en tant qu'agents immunothérapeutiques contre le cancer

Also Published As

Publication number Publication date
AU2020214628B2 (en) 2025-08-14
EP3917536A1 (fr) 2021-12-08
JP2022523105A (ja) 2022-04-21
IL323577A (en) 2025-11-01
KR20210124265A (ko) 2021-10-14
JP2025098199A (ja) 2025-07-01
PE20212306A1 (es) 2021-12-10
JP7777332B2 (ja) 2025-11-28
WO2020160333A1 (fr) 2020-08-06
CN113677350B (zh) 2025-01-14
MX2021009269A (es) 2021-08-24
CO2021010186A2 (es) 2021-10-29
CL2021002002A1 (es) 2022-03-11
AU2020214628A1 (en) 2021-08-12
CN113677350A (zh) 2021-11-19
AU2020214628C1 (en) 2026-02-26
EP3917536A4 (fr) 2022-11-23
PH12021551833A1 (en) 2022-03-21
AU2025267426A1 (en) 2025-12-04
TW202214571A (zh) 2022-04-16
SG11202108288YA (en) 2021-08-30
IL284961B1 (en) 2025-11-01
US20220289775A1 (en) 2022-09-15
US20250059218A1 (en) 2025-02-20
CA3128044A1 (fr) 2020-08-06
TW202515857A (zh) 2025-04-16
BR112021015098A2 (pt) 2022-01-11
TWI849048B (zh) 2024-07-21
IL284961A (en) 2021-09-30
IL284961B2 (en) 2026-03-01

Similar Documents

Publication Publication Date Title
MA54879A (fr) Inhibiteurs d'enpp1 et méthodes de modulation de réponse immunitaire
EP3700527A4 (fr) Inhibiteurs de papd5 et leurs méthodes d'utilisation
MA54952A (fr) Conjugués d'il-2 et méthodes d'utilisation de ceux-ci
EP3852805A4 (fr) Anticorps anti-lilrb2 et leurs méthodes d'utilisation
EP3820496A4 (fr) Constructions de fusion et leurs méthodes d'utilisation
EP3684361A4 (fr) Inhibiteurs substitués de ménine-mll et méthodes d'utilisation
MA50957A (fr) Anticorps anti-tigit et leurs méthodes d'utilisation
EP3723803A4 (fr) Anticorps anti-trem2 et méthodes associées
EP3917564A4 (fr) Anticorps anti-claudine 18 et leurs méthodes d'utilisation
MA45123A (fr) Anticorps anti-tim-3 et leurs méthodes d'utilisation
EP3510152A4 (fr) Méthodes et compositions pour moduler l'expression génique
EP3525583A4 (fr) Anticorps anti-c1s et leurs méthodes d'utilisation
MA48579A (fr) Anticorps anti-pd1 et méthodes d'utilisation de ceux-ci
MA42925A (fr) Anticorps anti-tigit et méthodes d'utilisation
MA48462A (fr) Formulations d'anticorps anti-rankl humains, et leurs méthodes d'utilisation
EP3334765A4 (fr) Récepteurs d'antigènes chimériques basés sur des anticorps à domaine unique et leurs méthodes d'utilisation
EP3383431A4 (fr) Anticorps anti-gitr et leurs méthodes d'utilisation
MA50354A (fr) Anticorps ciblant le cd137 et leurs méthodes d'utilisation
EP3684819A4 (fr) Anticorps anti-ykl40 et méthodes d'utilisation
EP3728323A4 (fr) Anticorps anti-fzd et méthodes d'utilisation
EP4004051A4 (fr) Anticorps immunomodulateurs et leurs méthodes d'utilisation
EP3655001A4 (fr) Méthodes d'aphérèse et utilisations associées
EP4146269A4 (fr) Inhibiteurs d'enpp1 et méthodes de modulation de réponse immunitaire
EP3735242A4 (fr) Inhibiteurs de la métallo-bêta-lactamase et leurs méthodes d'utilisation
EP3893931A4 (fr) Méthodes d'utilisation d'anticorps anti-trem2